Globus Medical, Inc. (NYSE:GMED) Short Interest Down 30.1% in February

Key Points

• Short interest plunged 30.1% in February to 3,270,517 shares (about 3.0% of shares sold short) with a days‑to‑cover of 2.3.
• Insiders sold 35,594 shares last quarter (≈$3.33M), including sales by Director Leslie Norwalk and CFO Kyle Kline, while insiders still own 18.51% of the stock.
• Globus beat estimates with $1.28 EPS vs. $1.06 and revenue of $826.4M (+25.7% YoY), prompting more bullish analyst actions and a consensus rating of Moderate Buy with an average target of $104.36 (Piper Sandler $115).

Globus Medical, Inc. (NYSE:GMED - Get Free Report) was the recipient of a large drop in short interest during the month of February. As of February 27th, there was short interest totaling 3,270,517 shares, a drop of 30.1% from the February 12th total of 4,675,619 shares. Approximately 3.0% of the company's shares are sold short. Based on an average trading volume of 1,421,356 shares, the days-to-cover ratio is currently 2.3 days. Based on an average trading volume of 1,421,356 shares, the days-to-cover ratio is currently 2.3 days. Approximately 3.0% of the company's shares are sold short.

Insider Transactions at Globus Medical

In related news, Director Leslie V. Norwalk sold 2,000 shares of Globus Medical stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $101.10, for a total transaction of $202,200.00. Following the completion of the transaction, the director directly owned 10,419 shares of the company's stock, valued at approximately $1,053,360.90. The trade was a 16.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Kyle Kline sold 3,594 shares of the company's stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $101.10, for a total transaction of $363,353.40. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 35,594 shares of company stock worth $3,332,253. 18.51% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Globus Medical

Several hedge funds have recently modified their holdings of GMED. SBI Securities Co. Ltd. increased its holdings in Globus Medical by 98.2% during the fourth quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company's stock valued at $29,000 after buying an additional 167 shares during the period. Wealth Enhancement Advisory Services LLC boosted its position in Globus Medical by 2.8% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 6,316 shares of the medical device company's stock valued at $375,000 after acquiring an additional 170 shares in the last quarter. Parallel Advisors LLC boosted its position in Globus Medical by 45.1% during the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company's stock valued at $32,000 after acquiring an additional 173 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Globus Medical by 14.7% in the 3rd quarter. GAMMA Investing LLC now owns 1,438 shares of the medical device company's stock valued at $82,000 after acquiring an additional 184 shares during the period. Finally, EverSource Wealth Advisors LLC increased its holdings in shares of Globus Medical by 74.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company's stock valued at $27,000 after acquiring an additional 197 shares during the period. Hedge funds and other institutional investors own 95.16% of the company's stock.

Globus Medical Price Performance

Shares of GMED stock traded up $0.30 during mid-day trading on Friday, hitting $84.81. The stock had a trading volume of 1,252,169 shares, compared to its average volume of 1,114,077. Globus Medical has a 12-month low of $51.79 and a 12-month high of $101.40. The firm has a market capitalization of $11.47 billion, a P/E ratio of 21.52, a price-to-earnings-growth ratio of 1.99 and a beta of 1.05. The firm's 50-day moving average is $90.71 and its two-hundred day moving average is $78.37.

Globus Medical (NYSE:GMED - Get Free Report) last announced its quarterly earnings results on Tuesday, February 24th. The medical device company reported $1.28 EPS for the quarter, beating the consensus estimate of $1.06 by $0.22. The firm had revenue of $826.42 million for the quarter, compared to analyst estimates of $803.29 million. Globus Medical had a return on equity of 12.57% and a net margin of 18.30%.The business's revenue for the quarter was up 25.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.84 earnings per share. Analysts expect that Globus Medical will post 3.44 EPS for the current year.

Analyst Ratings Changes

GMED has been the topic of a number of analyst reports. Piper Sandler reaffirmed an "overweight" rating and set a $115.00 target price (up from $90.00) on shares of Globus Medical in a research note on Thursday, January 8th. Citigroup restated a "market perform" rating on shares of Globus Medical in a report on Thursday, January 8th. TD Cowen raised Globus Medical to a "strong-buy" rating in a research report on Tuesday, January 27th. Zacks Research upgraded Globus Medical from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, March 3rd. Finally, Royal Bank Of Canada lifted their target price on Globus Medical from $92.00 to $100.00 and gave the stock an "outperform" rating in a research report on Wednesday, December 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, Globus Medical has a consensus rating of "Moderate Buy" and an average target price of $104.36.

Key Headlines Impacting Globus Medical

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Zacks Research sharply raised EPS forecasts across multiple quarters and years and maintained a "Strong‑Buy" rating — the firm bumped Q1, Q2 and Q3 2027 estimates and raised FY2026 and FY2027 outlooks (FY2027 to $4.66). Improved analyst earnings trajectories support higher forward valuations and raise the bar for future guidance. Zacks Research Raises Earnings Estimates for Globus Medical
• Positive Sentiment: Brokerage consensus sits at an average "Moderate Buy" rating — this aggregate analyst view suggests continued institutional support and can attract momentum buying as earnings estimates move higher. Globus Medical Given Average Rating of "Moderate Buy" by Brokerages
• Neutral Sentiment: Technical/valuation context is mixed — GMED is trading above its 200‑day moving average (longer‑term support) but below its 50‑day average (shorter‑term momentum). The stock still trades at a mid‑teens to low‑20s P/E on forward estimates, so further upside may depend on continued estimate upgrades or stronger organic revenue/ margin beats. MarketBeat GMED Page

About Globus Medical

Globus Medical, Inc NYSE: GMED is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.